thiazolidinediones

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril

Lori Wiviott Tishler, MD, MPH

Assistant Professor of Medicine, Harvard Medical School

Doctors are often hesitant to prescribe newer drugs. We simply can’t know everything about them until the experiences of early adopters tell us what they’re really like. Such is the case with thiazolidinediones. Some of the more recent diabetes drugs fell out of favor, but a new study suggests that may be helpful for very specific types of patients.